See what’s happening at MBC BioLabs.
Astellas Future Innovator Prize 2025
Astellas Pharma U.S. Inc., and MBC BioLabs announced their collaboration on the Astellas Future Innovator Prize. The competition offers entrepreneurial scientists and emerging biotechnology start-ups one year’s priority usage of MBC BioLabs’ state-of-the-art Bay Area facilities and access to Astellas’ research and development capabilities and business leaders.
Proposals due by April 1, 2025
BioInnovation Labs (BioLabs), LabCentral and MBC BioLabs Announce Strategic Partnership with AbbVie to Boost Innovation in key biotech clusters in the US and Europe.
BioLabs, LabCentral and MBC BioLabs are excited to announce a five-year strategic partnership with AbbVie, a global biopharmaceutical company. AbbVie has long been a champion of the three organizations’ shared vision for advancing biotech entrepreneurship and continues to play a critical role in the networks they have cultivated over the past decade.
BridgeBio’s Attruby™ (acoramidis) approved by FDA to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients
The U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.
Astellas Pharma U.S. Inc., and MBC BioLabs announced their collaboration on the Astellas Future Innovator Prize. The competition offers entrepreneurial scientists and emerging biotechnology start-ups one year’s priority usage of MBC BioLabs’ state-of-the-art Bay Area facilities and access to Astellas’ research and development capabilities and business leaders.
Proposals due by April 1, 2025
BioLabs, LabCentral and MBC BioLabs are excited to announce a five-year strategic partnership with AbbVie, a global biopharmaceutical company. AbbVie has long been a champion of the three organizations’ shared vision for advancing biotech entrepreneurship and continues to play a critical role in the networks they have cultivated over the past decade.
The U.S. Food and Drug Administration (FDA) approved Attruby™ (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. The FDA approval is based on positive results seen in the ATTRibute-CM Phase 3 study, where Attruby significantly reduced death and cardiovascular-related hospitalization, and improved quality of life.
Navigating Policy Shifts at the FDA, USPTO, and NIH: Strategic & Legal Insights for Biotech Entrepreneurs
March 18 @ 2pm – 3pm
Location:
135 Mississippi · San Francisco
Founders at Work: Arda Therapeutics
March 19 @ 12pm – 1pm
Location:
930 Brittan Ave · San Carlos
UCSF Women’s Innovation & Entrepreneurship Networking Event
March 26 @ 5pm – 7pm
Location:
135 Mississippi · San Francisco
Founders at Work: Junevity
April 16 @ 12pm – 1pm
Location:
135 Mississippi St · San Francisco
Women’s Health Innovation Forum
April 24 @ 1pm – 5:30pm
Location:
1030 Brittan Ave · San Carlos
Founders at Work: Siren Biotechnology
May 1 @ 12pm – 1pm
Location:
135 Mississippi St · San Francisco
Fika, A New MBC BioLabs Tradition!
According to Doug Crawford, there are a few key things that scientists need in order to succeed in the labs: one of them being coffee, and the other is snacks! Our newly adapted weekly tradition of Fika was inspired by the Swedish culture. Fika, which roughly translates from Swedish as drinking coffee, munching sweet treats and chatting — is as much a part of the working day in Sweden as emailing and fixing the printer.
